Table 1 General and clinical characteristics of the sample studied (n = 117)
|  | Mean (SD) | Median (Min–Max) |
|---|---|---|
Age (years) | 53,3 (12,1) | 50,0 (30–88) |
BMI ( (kg/m2) | 26,4 (5,0) | 25,5 (17,3–38,2) |
Charlson Comorbidity Index | 4,4 (2,1) | 6,0 (0–8) |
Age-Adjusted Charlson Comorbidity Index | 5,1 (2,5) | 6 (0–11) |
Time of evolution of cancer (months) | 11,2 (18,5) | (2–139) |
| Â | n (%) | 95% CI |
Civil status | ||
 Single | 22 (19,0) | 11,3–26,3 |
 Married / Co-habitant | 78 (67,2) | 57,7–75,6 |
 Widow | 8 (6,9) | 1,8–11,8 |
 Divorced / Separated | 8 (6,9) | 1,8–11,8 |
Education level | ||
 No studies | 4 (3,4) | 0,9–8,5 |
 Primary studies | 15 (12,9) | 6,3–19,3 |
 Secondary/Higher Education | 60 (51,7) | 41,8–60,8 |
 University studies | 37 (31,9) | 22,7–40,5 |
Employment situation | ||
 Active | 4 (3,4) | 0,9–8,5 |
 Unemployed | 5 (4,3) | 1,4–9,7 |
 Pension | 16 (13,8) | 7,0–20,3 |
 Sick leave | 67 (57,8) | 47,9–66,6 |
 Inability to work | 5 (4,3) | 1,4–9,7 |
 Household | 14 (12,1) | 5,6–18,3 |
Smoking habit | ||
 Yes | 8 (6,9) | 1,8–11,8 |
 Former smoker | 33 (28,4) | 19,6–36,8 |
Breast cancer | ||
 Invasive ductal | 107 (92,2) | 85,9–96,9 |
 Invasive lobuar | 9 (7,8) | 2,4–12,9 |
Breast Cancer Subtype | ||
 Luminal A | 2 (1,7) | 0,2–6,0 |
 Luminal B HER2 negative | 54 (46,2) | 36,7–55,6 |
 Luminal B HER2 positive | 33 (28,2) | 19,6–36,8 |
 Triple Negative | 21 (17,9) | 10,6–25,3 |
 HER 2 positive | 7 (6,0) | 1,2–10,7 |
Metastasis | 59 (50,4) | 39,2–58,2 |
Cancer therapy | ||
 Chemotherapy or after finishing it | 82 (70,2) | 61,4–78,8 |
 Anti-HER2 Therapy after chemotherapy | 11 (9,4) | 3,7–15,1 |
 Chemotherapy + Anti-HER 2 Therapy | 11 (9,4) | 3,7–15,1 |
Number of cycles received at time of visit | ||
 4 cycles | 34 (29,1) | 20,4–37,7 |
 5 cycles | 17 (14,5) | 7,7–21,3 |
 6 cycles | 11 (9,4) | 3,7–15,1 |
 8 cycles | 25 (21,4) | 13,5–29,2 |
 Others | 30 (25,6) | 17,3–34,0 |